H. Portengen

发表

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

N. Brünner, J. Foekens, J. Klijn, 2000, Cancer research.

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

Maurice P H M Jansen, Maxime P Look, J. Foekens, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.

J. Foekens, J. Klijn, H. Peters, 1989, Cancer research.

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

J. Foekens, J. Klijn, M. Look, 1995, Journal of the National Cancer Institute.

The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study

J. Foekens, J. Klijn, M. Look, 2004, Breast Cancer Research and Treatment.

Complete Sequencing of TP 53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer 1

R. Vossen, J. Foekens, J. Klijn, 2000 .

Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs

J. Foekens, M. Blankenstein, C. Cornelisse, 2004, Breast Cancer Research and Treatment.

Insulin‐like growth factor‐1 receptors and insulin‐like growth factor‐1‐like activity in human primary breast cancer

J. Foekens, J. Klijn, H. Portengen, 1989, Cancer.

Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies

J. Foekens, J. Klijn, H. Portengen, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.

H. Portengen, J. Alexieva-Figusch, M. Henkelman, 1980, Cancer research.

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Maxime P Look, R. Vossen, J. Foekens, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

J. Foekens, J. Klijn, B. Thirion, 1994, British Journal of Cancer.

Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer

J. Foekens, J. Klijn, H. Portengen, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.

J. Foekens, J. Klijn, M. Look, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.

J. Foekens, J. Klijn, H. Portengen, 1989, Endocrinology.

How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study

Mieke Timmermans, J. Foekens, J. Klijn, 2005, Clinical Cancer Research.

CHEK2 1100delC and male breast cancer in the Netherlands

J. Foekens, J. Klijn, M. Schutte, 2009, Breast Cancer Research and Treatment.

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients

John W. M. Martens, Manfred Schmitt, Nadia Harbeck, 2008, Breast Cancer Research and Treatment.

Ectopie Expression of Epidermal Growth Factor Receptors Induces Hormone Independence in ZR-751 Human Breast Cancer Cells 1

J. Foekens, T. Agthoven, T. Agthoven, 2006 .

Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells.

J. Foekens, T. Agthoven, T. Agthoven, 1992, Cancer research.

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

R. Vossen, J. Foekens, J. Klijn, 2000, Cancer research.

Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.

J. Foekens, J. Klijn, E. Berns, 1992, European journal of cancer.

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

J. Foekens, J. Klijn, H. Portengen, 1989, Cancer research.

c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.

J. Foekens, J. Klijn, E. Berns, 1992, Cancer research.

Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue.

J. Foekens, C. Sweep, P. Span, 2004, Clinical chemistry.

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

J. Foekens, J. Klijn, J. Verweij, 1990, British Journal of Cancer.

The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors

J. Foekens, J. Klijn, S. Lamberts, 1990, Breast Cancer Research and Treatment.

Expression of tumor‐associated 90k‐antigen in human breast cancer: No correlation with prognosis and response to first‐line therapy with tamoxifen

J. Foekens, M. Look, H. Portengen, 1995, International journal of cancer.

Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.

J. Foekens, B. Thirion, H. Portengen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new aspect of the urinary excretion of tryptophan metabolites in patients with cancer of the bladder

H. Peters, H. Portengen, W. Haije, 1978, International journal of cancer.

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.

J. Foekens, J. Klijn, E. Berns, 1995, Gene.

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.

John W M Martens, Fabian Model, Christian Piepenbrock, 2005, Cancer research.

Patients with Recurrent Breast Cancer Aminotransferase with Response to Endocrine Therapy in Association of DNA Methylation of Phosphoserine

J. Foekens, J. Klijn, H. Höfler, 2005 .

The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer

J. Foekens, J. Klijn, M. Look, 2004, Clinical Cancer Research.

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features

J. Foekens, J. Klijn, M. M. Gelder, 2001, British Journal of Cancer.

Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors.

J. Foekens, J. Klijn, E. Berns, 1992, Cancer research.

Comparison of enzyme immunoassay and dextran-coated charcoal techniques for progesterone receptor determination in human breast cancer cytosols.

J. Foekens, J. Klijn, H. Portengen, 1988, Journal of steroid biochemistry.

Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification

J. Foekens, J. Klijn, E. Berns, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Prophylactic neuropeptide-analog treatment of a transplantable pancreatic tumor in rats

J. Foekens, J. Klijn, H. Portengen, 1987 .

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.

Mieke Timmermans, Maxime P Look, J. Foekens, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients

J. Foekens, J. Klijn, A. Sieuwerts, 2006, Clinical Cancer Research.

Quantitation of estrogen receptors in human breast cancer by agar gel electrophoresis.

H. Portengen, M. Henkelman, H. van Gilse, 1975, Clinica chimica acta; international journal of clinical chemistry.